Eli Lilly and Company says it has decided to discontinue trials for schizophrenia drug pomaglumetad methionil (mGlu2/3) because of unfavorable results. The company says that two pivotal studies did not look as though they would have positive results regarding their primary efficacy endpoint. The company stresses that the discontinuation was not due to any safety issues. It's recent Phase II study which looked at using pomaglumetad methionil alongside antipsychotic medications did not meet its primary endpoint either...
Indique esta NotÃcia
Compartilhar
